Endpoints News
Lilly makes a splash at #EASD26 Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
M T Wed Th F
30 September, 2026
sponsored by Cambrex logo
Continuous Manufacturing: An Evolving Technology for Drug Substance Manufacturing
Continuous manufacturing is transforming how complex drug substances are developed and produced. This article explores how pharmaceutical manufacturers are using continuous flow technologies to safely scale challenging chemistries, improve process efficiency, and accelerate development timelines. Through real-world examples spanning organometallic reactions, hazardous reagents, photochemistry, and membrane separations, discover why hybrid manufacturing strategies are becoming essential tools for overcoming modern drug development challenges.
Read the Article
top stories
1. Varda gets $251M to make medicines in space, a long-sought area for drugs
2. Lilly's amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetes
3. Ned Sharpless joins Hatteras, as Andrew Witty returns to the VC firm as chairman
4.
news briefing
AbbVie's eczema drug shows benefit in Phase 2; BioMarin lays off 117
5. Lilly's triple-G allows more than half of patients to drop below obesity line
6. Merck shows off mid-stage win for Prometheus drug in painful skin disease
7. Zealand and Roche's amylin works best at middle dose, trails Lilly's
8. PhRMA picks Eric Cantor as next chief
more stories
• 
Karen Weintraub
.

Gravity is a tool like temperature, the president of Varda Space Industries told Kyle LaHucik. And Delian Asparouhov plans to use what he sees as the advantages of microgravity for making innovative drugs. Read more here.
.
Karen Weintraub
Deputy Editor, Endpoints News
1
by Kyle LaHucik

A Cal­i­for­nia start­up has raised a $251 mil­lion Se­ries D to ad­vance phar­ma­ceu­ti­cal man­u­fac­tur­ing in space, long seen as the next fron­tier for drug de­vel­op­ment...

Read the full story
Lilly at the EASD Annual Meeting in Milan (Elizabeth Cairns for Endpoints News)
2
by Elizabeth Cairns

MI­LAN — For­get We­govy and Zep­bound. Nev­er mind Ca­griSe­ma, and even re­ta­tru­tide. The lat­est big name in obe­si­ty is elo­raTZP.

Da­ta re­vealed Wednes­day show that...

Read the full story
Ned Sharpless, Hatteras Venture Partners managing director
3
by Kyle LaHucik

Hat­teras Ven­ture Part­ners, a North Car­oli­na VC firm that has backed 100 life sci­ences star­tups, an­nounced Wednes­day that it has at­tract­ed for­mer Na­tion­al Can­cer...

Read the full story
News Briefing: Quick hits from the biopharma web
4
by ENDPOINTS

Plus news about Sarep­ta, Rafael Hold­ings, Sagimet, Pyx­is On­col­o­gy, Con­nect Bio­phar­ma, Asahi Ka­sei, As­tro­cyte Phar­ma­ceu­ti­cals, GSK, Wave and Kail­era.

Ab­b­Vie un­veils Phase 2 da­ta for...

Read the full story
5
by Elizabeth Cairns

MI­LAN— Eli Lil­ly said Tues­day that its triple ag­o­nist re­ta­tru­tide helped pa­tients with both obe­si­ty and type 2 di­a­betes lose up to 18.8% of...

Read the full story
6
by Max Gelman